733 results about "Endocrine secretion" patented technology

The present invention relates to various molecular constructs having at least one cellular-targeting element, one protein-targeting element, and one ubiquitin ligase recruitment element, wherein these elements are conjugated in a manner that facilitates cellular uptake and targeted degradation of specific proteins within cells. The present invention further relates to multifunctional proteolysis-targeting chimera conjugates and uses thereof for the treatment of diseases or disorders such as immune and inflammatory diseases, infectious diseases, cardiovascular diseases, endocrine disorders, and various cancers that are otherwise resistant to traditional therapeutic regimens.

The invention discloses a health degree assessment system and method for endocrine nursing, and relates to the technical field of health assessment, and the system comprises a state vector construction module which is used for collecting basic data of a patient, constructing an individual state vector S, collecting physiological data of the patient in real time, and extracting deep features by using a CNN model; and the anomaly detection module is used for performing dimensionality reduction on the deep features by using PCA, then inputting a mutation point detection algorithm to detect periodic mutation points to obtain a mutation point set, identifying peak activation response by using SNN to obtain a peak anomaly set, and integrating the obtained mutation point set and the peak anomaly set into an anomaly feature vector A. According to the method, dynamic and accurate evaluation of the health state of the endocrine patient is achieved, accurate multi-symptom risk prediction can be achieved through real-time monitoring and automatic recognition of hormone fluctuation, behavior abnormity and health state changes, a personalized nursing intervention plan can be generated according to the individual health state, and therefore the nursing efficiency is improved.

The invention belongs to the field of biological medicines, and particularly relates to application of FeTMPyP in preparation of a medicine for relieving ovarian toxicity. FeTMPyP is selected as an intervention agent aiming at the fact that MC-LR and NaNON combined exposure can remarkably induce mouse ovary nitration stress, mouse follicle barrier damage and ovarian reproductive endocrine dysfunction; the FeTMPyP can be used for effectively relieving nitration stress induced by combined exposure of MC-LR and NaNO2 in mouse ovaries, improving sex hormone disorder, disordered estrus cycle and follicular atresia phenomena caused by combined exposure of the two poisons, and recovering the fertility of the mouse, so that the intervention of the FeTMPyP can be used for relieving the mouse ovarian toxicity induced by combined exposure of MC-LR and NaNO2, and can be used for treating the ovarian toxicity of the mouse caused by combined exposure of the MC-LR and NaNO2. The compound can be used for preparing medicines for preventing and treating related diseases such as mouse ovarian toxicity caused by environmental toxin exposure, and a new way is provided for early recognition and targeted intervention of ovarian related diseases.

The invention discloses a prostate cancer endocrine therapy drug resistance prediction system based on multi-model artificial intelligence. The prostate cancer endocrine therapy drug resistance prediction system comprises a data acquisition and preprocessing module, a single omics prediction module, a multi-modal feature integration module, a model training module and a prediction result output module. Multi-omics data of a patient is collected and preprocessed, data representations of omics data of different labels are generated by using priori knowledge, and an optimal single-omics prediction model is matched for the omics data of different labels based on the data representations after knowledge enhancement. And constructing a multi-omics prediction model of the prostatic cancer endocrine treatment drug resistance by using the optimal single-omics prediction model corresponding to the different label medical data by adopting Stacking, predicting the drug resistance risk of the patient within a preset time, outputting an early warning, and adjusting the treatment scheme of the patient according to the drug resistance risk. According to the method, the multi-omics data are integrated, the accurate multi-omics prediction model for the drug resistance of the endocrine therapy of the prostate cancer is constructed, and the accuracy and clinical applicability of drug resistance prediction are improved.

The invention discloses a 3D intestinal organ differentiation method based on human pluripotent stem cells and an induction culture medium and application thereof, and relates to the technical field of stem cells. According to a culture medium formula combination, intestinal organs can be differentiated into various cell types such as epithelial cells, neuroendocrine cells and endothelial cells; the method is a key mark for successful differentiation and functional maturation of intestinal organs. According to the 3D intestinal organ differentiation method disclosed by the invention, histological structures such as intestinal crypts are differentiated from intestinal organs generated by differentiation, and the intestinal organs can creep in a maintenance stage, so that the intestinal organs are changed from structural bionics to functional simulation, and the significance of the 3D intestinal organ differentiation method is far better than that of pure morphological simulation. Through a systematic culture medium formula, a clear operation process and a multi-stage induction strategy, the 3D intestinal organ with structural integrity, cell diversity and functional activity is successfully constructed, and the system provides an efficient, reliable and extensible in-vitro model platform for intestinal biological research and related application.

The invention relates to the technical field of medical health management, and discloses an endocrine patient health management system based on big data. According to the system, a multi-source data acquisition module is adopted to acquire heterogeneous health data including physiological monitoring indexes, medication record data, medical image reports and the like, and living habit logs can also be included. The physiological feature noise reduction module is used for extracting steady-state physiological features, the multi-modal fusion module is used for generating a focus dynamic map, and the medication feedback analysis module is used for generating a drug response mode evolution sequence. The data are input into a multi-dimensional decision model, and a health management scheme is output by a personalized scheme generation module. And the living habit analysis module analyzes the living habit logs to generate influence factors, and participates in making a health management scheme. The system realizes multi-source data fusion analysis, can provide a personalized health management scheme for an endocrine patient, improves the disease diagnosis accuracy and treatment effect, and improves the life quality of the patient.

The invention discloses an endocrine disruption effect harmful outcome path network construction method, and relates to the field of endocrine disrupter screening, and the method comprises the steps: obtaining endocrine data; preprocessing the acquired endocrine data; according to the preprocessed endocrine data, constructing an event causal relationship triad reflecting the endocrine disruption effect, wherein the event causal relationship triad comprises a trigger word, a source event and a target event; the data KER1 is used as data KER1; according to the preprocessed endocrine data, acquiring endocrine data of which the confidence coefficient is greater than a preset threshold value from a preset literature database, and taking the acquired endocrine data as data KER2; performing duplicate removal processing on the data KER1 and the data KER2 to obtain final endocrine disruption effect harmful outcome path data; and establishing an endocrine disruption effect harmful outcome path network according to the final endocrine disruption effect harmful outcome path data. In view of insufficient analysis of an action mechanism between an endocrine disrupter and a corresponding bad health outcome in the prior art, the application improves interpretability.

The invention discloses a classification method and a classification device for pancreatic neuroendocrine tumors. The classification method comprises the following steps: using a pre-trained segmentation model to segment a plurality of HE full slice images from a plurality of patients; quantizing each segmented HE full slice image to determine a plurality of first feature parameters; based on the cellular morphology and topological features of each HE full-slice image, extracting a plurality of second feature parameters from each HE full-slice image; for each HE full slice image, screening out a target feature from the plurality of first feature parameters and the plurality of second feature parameters, and calculating a pathological omics score; inputting the pathological omics scores and the conventional pathological features of the plurality of HE full slice images into a logistic regression model for training to obtain a trained logistic regression model; and classifying the HE full slice images to be classified by using the logistic regression model. According to the method, pancreatic neuroendocrine tumor G classification can be quickly and accurately realized at low cost.

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

The invention relates to the technical field of blood pressure dynamic monitoring systems, and provides an artificial intelligence-based blood pressure dynamic monitoring and risk assessment system, which comprises a patient terminal, a doctor terminal, a data center terminal, a local anomaly detection terminal and a strategy generation terminal, the patient terminal is used for collecting blood pressure, body position change and endocrine hormone fluctuation data of a patient in real time; the data center terminal is used for fusing, storing and processing the data uploaded by the patient terminal and performing overall risk assessment; the local anomaly detection terminal is used for collecting local blood flow rate and pulse wave conduction velocity data and carrying out local anomaly detection index analysis; the strategy generation terminal is used for generating strategy information according to the overall risk assessment result and the local anomaly detection index; and the doctor terminal is used for receiving and displaying the overall risk assessment result and the local anomaly detection index, and receiving and executing the strategy information. According to the invention, the comprehensiveness and timeliness of hypertension risk prediction and intervention are improved.

The invention relates to the technical field of medical syringes, and discloses an endocrine hormone injection auxiliary device, which comprises a syringe mechanism, a needle cylinder mechanism, a needle cylinder mechanism, a needle cylinder mechanism and a needle cylinder mechanism, and the constant pressure mechanism is arranged on the needle cylinder and is used for providing constant pressure to drive the cylinder piston. According to the endocrine hormone injection auxiliary device, a constant-pressure mechanism is arranged, based on the conversion principle of gravity and air pressure, the gravity is converted into constant air pressure by placing a weight with the fixed weight on a top light disc, and a cylinder piston is pushed to move in a needle cylinder at the uniform speed; and the problem of unstable injection speed caused by non-uniform hand force during manual injection is avoided. Meanwhile, the moving distance of the top light disc is accurately controlled by rotating the threaded rod, then the amount of air extruded out of the middle corrugated pipe is determined, accurate control over the liquid medicine output amount is achieved, and the requirements of patients with chronic diseases or the weak for accurate, stable and slow injection are met.

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

The invention discloses DLL3 serving as a cervical neuroendocrine cancer treatment target and application of the DLL3, and belongs to the technical field of biology. The invention discloses specific expression of a DLL3 gene in cervical neuroendocrine carcinoma (NECC) and application of the DLL3 gene as a therapeutic target. Single cell sequencing and immunohistochemistry find that a DLL3-NOTCH1 / 2 signal axis is activated in NECC, and functional experiments prove that the DLL3-NOTCH1 / 2 signal axis drives malignant progression by promoting tumor proliferation and inducing T cell depletion. In addition, the invention also constructs an NECC organ-TILs co-culture model, and verifies the synergistic effect of the DLL3 targeted drug AMG757 combined with EP chemotherapy. The invention provides new target selection and theoretical basis for precise diagnosis and treatment of NECC, and has important clinical transformation value.

The invention provides a preparation method of 1-(3-bromo-4-(2-fluoro [18F] ethyoxyl) ethyoxyl) benzyl guanidine (called 18F-TTRC01) and application of the 1-(3-bromo-4-(2-fluoro [18F] ethyoxyl) ethyoxyl) benzyl guanidine in the field of neuroendocrine tumor diagnosis. The compound is synthesized through the following route. According to the invention, a brand new initial raw material and a preparation route are adopted, a large dose of 18F ions are used for labeling, and an automatic synthesis mode is adopted to successfully prepare the 18F-TTRC01, so that the reaction time is greatly shortened, and the radiation dose to operators is reduced. The obtained 18F-TTRC01 injection can be used for diagnosis and curative effect evaluation of neuroendocrine tumors, and has an outstanding clinical effect. # imgabs0 #

The invention relates to the field of animal consumer goods, and particularly discloses application of glucan in preparation of animal products for relieving pet stress syndromes. Pet experiments find that beta-1, 3 / alpha-1, 3-glucan can improve the stress syndromes of the indoor cats, specifically, abnormal behaviors of the cats are corrected, and abnormity of multiple systems of organisms such as the immune system, the endocrine system and the urinary system is improved. And when the method is applied to pets, the life quality of the pets can be remarkably improved, more emotional support is provided for pet owners, and the method has practical popularization and application values.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The invention relates to the technical field of medical information, in particular to an endocrine patient long-term medication tracking management method and system, and the method comprises the following steps: extracting multiple pieces of key information in a prescription based on the electronic prescription information of a patient, recognizing the taking time and dosage information of multiple medicines, and sending medication reminding information to the patient, by monitoring the opening and closing state of the medicine box, the medicine taking time and quantity are recorded, and reminding and medicine taking monitoring information is generated. According to the method, the opening and closing state of the medicine box is monitored in real time, the taking time and quantity of medicine are recorded, the transparency of medicine treatment and the compliance of a patient are improved, physiological parameters of the patient are collected regularly, time sequence analysis and doctor feedback are matched, the change trend and periodic fluctuation of the illness state of the patient are accurately recognized, and the patient compliance is improved. By analyzing drug use logs of patients and doctors, effects of various drugs are identified, side effects are detected, drug doses and types are helped to be adjusted in time, the risk of adverse drug reactions is effectively reduced, and the treatment effect is improved.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

Provided are TYK2 inhibitors of Formula I, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. These compounds are useful, for example, in treating TYK2-mediated disorders, such as, autoimmune and inflammatory disorders, metabolic disorders, proliferative disorders, endocrine disorders, neurological disorders, allergic disorders, and disorders associated with transplantation.

The invention relates to the technical field of data analysis, can be applied to business system platforms of financial science and technology, medical treatment and health and the like, and discloses a human body state characteristic value analysis method, device and equipment and a medium. Performing system state analysis on an endocrine system, a circulatory system and a respiratory system of the user according to the physical examination data to obtain a system state characteristic value set, constructing a physiological index vector and a disease course characteristic vector according to the physical examination data, and constructing a complication incidence matrix according to case data; performing complication association analysis on the user according to the physiological index vector, the disease course feature vector and the complication association matrix to obtain a complication feature value, analyzing a criticality feature value of the user according to a system state feature value set and the complication feature value to obtain a hazard feature value set, and performing weighted summation on the hazard feature value set to obtain a complication feature value set; and obtaining a human body state characteristic value. And the accuracy of human body state characteristic value analysis is improved.

The invention relates to the technical field of microorganisms and fermentation engineering, in particular to a lactobacillus plantarum strain and a method for preparing a traditional Chinese medicine fermented beverage. The strain is preserved in Guangdong Microbial Culture Collection Center on December 13, 2024, and the preservation number is CGDMCC (China General Microbiological Culture Collection Center) NO: 65639. The invention provides a method for preparing a blood replenishing beverage by fermenting the strain, and the method comprises the following steps: mixing a traditional Chinese medicine extracting solution, a ginseng concentrated solution and pomegranate concentrated juice to obtain a mixed liquid medicine, and then inoculating lactobacillus plantarum YXLP-116 for fermentation. The fermented beverage has the effects of regulating internal secretion, improving reproductive health and relieving climacteric symptoms. Experimental results show that the beverage can significantly reduce the FSH and LH levels and improve the E2 level, and has high safety and cell protection effect. Animal experiments further prove the potential of the protein in the aspect of regulating endocrine.

The invention belongs to the technical field of biomedicine, and relates to a method for constructing a mouse embryo-derived hypothalamic organ model and application, the invention proposes that a mouse embryo is used for constructing a hypothalamic organ for the first time, and the mouse embryo has a definite development time sequence and genetic operability; the naturally retained vascular endothelial cells and multilineage precursor cells provide unique advantages for constructing a three-dimensional organ containing multiple nucleuses such as a preoptic region, a paraventricular nucleus, an arcuate nucleus and a supraoptic nucleus, and the model not only breaks through the nucleus coverage limitation of the existing iPSCs organ, but also can be used for constructing the three-dimensional organ containing multiple nucleuses such as the preoptic region, the paraventricular nucleus, the arcuate nucleus, the supraoptic nucleus and the like by reconstructing a nerve-blood vessel unit. High-fidelity simulation of complex physiological functions of the hypothalamus is realized, and an irreplaceable technical platform is provided for mechanism analysis of neuroendocrine diseases and high-throughput screening of drugs.

The present invention relates to the technical field of medical information management for the elderly endocrine system, and specifically relates to a method for risk assessment of elderly endocrine diseases based on big data. The present invention screens out all the highest similarity vectors of the target medical vector; obtains the basic risk factors according to the detection time distribution and similarity degree between the two; obtains the self-risk factors by combining the detection times of all medical vectors; obtains the data change risk factors according to the number of similar patients with the disease and the data difference and detection time difference between the medical vector and the first medical vector; obtains the endocrine system stability factor by using the similarity degree between medical vectors, combines them to obtain the dynamic risk factor, and further conducts a risk assessment of elderly endocrine diseases for the person to be evaluated. The present invention takes into account the physiological changes of the elderly population and the timeliness of risk factors, making the risk assessment of elderly endocrine diseases more accurate.

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Provided are a novel modified side chain, and a preparation method therefor and a use thereof. In particular, provided are a modified side chain as represented by general formula (I), and a preparation method therefor, a pharmaceutical composition containing same, and a use thereof in the preparation of drugs for treating cancer, infections, neuropsychiatric diseases, cardiovascular diseases, endocrine diseases, and immune-related diseases.

The invention relates to the technical field of medical detection, in particular to an endocrine hypertension screening method based on immunological analysis, which comprises the following steps: collecting a random urine sample, removing interferents by using a composite nano adsorbent, and synchronously detecting hormones such as aldosterone, methoxyadrenaline and cortisol and metabolites thereof by using a high-throughput immunity analyzer; integrating detection data based on a dynamic threshold algorithm to generate a screening report, carrying out weighted scoring on positive samples in combination with clinical features, screening high-risk candidate samples, carrying out 24-hour urine retest on the high-risk samples, and if a retest result is still positive, carrying out referral treatment to a specialized department for disease cause definite diagnosis; according to the method, the technical problems of complex sample treatment, low multi-step efficiency and high false positive rate in the prior art are solved, efficient and accurate screening of endocrine hypertension is realized, and reliable support is provided for early diagnosis and targeted treatment.

The invention discloses application of mangiferin in preparation of a protective agent for testicular sertoli cells and preparation of a medicine for treating male infertility diseases, and relates to the technical field of medicine application. Wherein the mangiferin can play a role in protecting the sertoli cells, and the protection role is reflected in ways of improving the cell viability of the sertoli cells, inhibiting the apoptosis of the sertoli cells, inhibiting the oxidative stress of the sertoli cells, inhibiting the inflammatory response of the sertoli cells and the like; meanwhile, mangiferin can be used for treating male infertility diseases in ways of relieving weight loss, repairing testis, improving endocrine system functions, inhibiting oxidative stress of testis tissues, inhibiting inflammatory response of the testis tissues and the like. Wherein the mangiferin can inhibit the inflammatory reaction mainly by inhibiting the activation of NLRP3 inflammasome to inhibit the NLRP3 pathway, so that the inflammation and even pyroptosis of testicular sertoli cells are remarkably reduced to improve spermatogenesis, and the male infertility disease is well treated.

The invention belongs to the field of biological medicine, and provides circular RNA for treating multiple endocrine tumor type I and application of the circular RNA. According to the invention, after different optimization and design are carried out on the circular RNA for coding Menin, the circular RNA with relatively good expression level and long half-life period is finally obtained, and the anti-tumor effect is mainly achieved by supplementing cell-deficient Menin. Compared with the prior art, the circular RNA for expressing the Menin protein provided by the invention is more stable in intracellular expression and longer in half-life period. In an immortalized parathyroid gland cell model, the Menin protein can be expressed by transfecting the circular RNA for 6 hours, and the circular RNA has good treatment potential for multiple endocrine tumor type I.

The application provides a preparation method and application of oat active peptides for promoting GLP-1 secretion, wherein the oat active peptides contain any one or more of peptide segments NDQRGEII, KQGDVIALPA, PFVQQQQ and PSEQYQPYPEQQEPFVQ. The preparation method of the oat active peptides comprises enzymolysis, chemical synthesis or genetic engineering. The oat active peptides can significantly promote the secretion of GLP-1 by intestinal endocrine cells, and have the advantages of safe and non-toxic side effects, tolerance to gastrointestinal digestive enzyme hydrolysis and easy absorption. The application has simple operation, low requirement for equipment, is suitable for industrial large-scale production, and can be used for the development of new drugs for controlling blood sugar or food for assisting in controlling blood sugar, drugs for controlling body weight or food for assisting in controlling body weight and the like.